Biocryst Pharmaceuticals (BCRX) Profit After Tax (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Profit After Tax for 17 consecutive years, with $78.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax rose 1300.16% year-over-year to $78.4 million; the trailing twelve-month figure through Jun 2026 stood at -$384.9 million (down 986.22% YoY), and the FY2025 full-year result was $263.9 million, up 395.49% from the prior year.
• Profit After Tax advanced to $78.4 million in Q2 2026 per BCRX's latest filing, from -$721.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $245.6 million in Q4 2025 and bottomed at -$721.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$52.3 million across 5 years, with a median of -$35.8 million in 2023.
• The widest YoY moves for Profit After Tax: up 1300.16% in 2026, down 342191.0% in 2026.
• Over 5 years, Profit After Tax stood at -$71.4 million in 2022, then advanced by 13.56% to -$61.7 million in 2023, then jumped by 55.92% to -$27.2 million in 2024, then surged by 1002.67% to $245.6 million in 2025, then plunged by 68.08% to $78.4 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $78.4 million, -$721.8 million, and $245.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.